Toutes les études
RecrutementPHASE3INTERVENTIONNEL

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

This study is exploring whether a new medicine, spesolimab, can help adults with a skin condition called pyoderma gangrenosum (PG). The main goal is to see if spesolimab leads to the healing of PG ulcers. Participants will receive either spesolimab or a placebo (a dummy medicine) through a drip, along with steroid tablets initially. The study runs in two parts, with treatment assigned by chance. Doctors will regularly check participants' skin, health, and any side effects over about 1.5 years. The results will help determine if spesolimab is an effective treatment for PG.

En un coup d'œil

Statut
Recrutement
Phase
PHASE3
Sponsor
Boehringer Ingelheim
Objectif d'inscription
90
Démarrer
04 Feb 2025
Achèvement estimé
19 Aug 2028

De quoi parle cette étude ?

You might be reading this because you or someone you know has pyoderma gangrenosum (PG), a difficult skin condition. This study is looking into a new medicine called spesolimab. The main idea is to find out if spesolimab can help heal the ulcers (open sores) that are a common problem with PG. If it works, it could offer a new way to treat this condition.

The study involves adults who have ulcerative PG, meaning they have ulcers on their skin. The ulcers need to be a certain size to join the study. Researchers want to compare spesolimab with a placebo, which looks like the real medicine but doesn't contain any active ingredients. This helps them truly understand if the medicine itself is making a difference.

By taking part, you would be helping doctors and scientists learn more about PG and how to treat it. Every participant's experience provides valuable information, bringing us closer to better treatments for everyone with this condition.

Points clés

  • This study tests if spesolimab helps heal pyoderma gangrenosum (PG) ulcers.
  • It involves adults with specific types of PG ulcers.
  • You might receive spesolimab or a placebo, plus steroid tablets initially.
  • Treatment is given as a drip every four weeks.
  • The study lasts about 1.5 years with regular clinic visits.
  • Your participation helps to advance PG treatment research.

Qui peut être éligible ?

To be able to join this study, you need to be an adult, aged 18 or over. You must also have a clear diagnosis of ulcerative pyoderma gangrenosum (PG), which means you have ulcers on your skin related to this condition. These ulcers need to be a certain size, not too small and not too large (between 5 and 80 square centimetres).

Your PG ulcer should also have been diagnosed within the last six months, though some older, active ulcers might be considered. It's important that your ulcers are not infected when you start the study. Also, if you are a woman who could become pregnant, you'll need to agree to use effective birth control throughout the study.

You cannot join if you have other types of skin sores that are not PG, or if your PG ulcers are very large. Also, if your ulcers are chronic and don't respond to usual treatments that calm the immune system, you might not be suitable for this particular study.

Cet étude pourrait-elle vous convenir ?

Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.

  1. Avez-vous 18 ans ou plus ?
  2. Have you been diagnosed with ulcerative pyoderma gangrenosum (PG)?
  3. Do you have at least one PG ulcer between 5 and 80 square centimetres in size?
  4. Is your PG ulcer not currently infected?
  5. If you are a woman, are you willing to use effective birth control during the study?
  6. Do you not have other types of skin sores that are not PG?
Répondez à chaque question pour voir votre résultat.

En quoi consiste la participation ?

If you decide to join this study, it will last for about 1.5 years. During this time, you'll visit the study clinic 20 times. At these visits, doctors will carefully check your skin – especially your PG ulcers – to see how they are healing. They will also keep a close eye on your general health and write down any side effects you might experience.

In the study, you'll receive either the medicine spesolimab or a placebo (a dummy medicine) through a drip into your arm. This drip will be given every four weeks. For the first eight weeks, all participants will also take steroid tablets by mouth. The study involves two parts, and the treatment you receive will be decided by chance, meaning it's random.

If you have open ulcers, during the second part of the study, you will receive spesolimab. If your ulcers have healed, you might get either spesolimab or the placebo. You can also withdraw from the study at any time.

Risques et avantages potentiels

Taking part in a study like this might offer some potential benefits, such as receiving a new, experimental treatment that could help improve your pyoderma gangrenosum, access to specialist medical care, and contributing to medical science. However, there are also potential risks, as spesolimab is an investigational drug, and its full range of side effects might not be known yet. You will be closely monitored for any unwanted effects. It's important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (96)

  • Université de l'Alabama à Birmingham
    Code postal vérifié
    Birmingham, États-Unis· Recrutement
  • Medical Dermatology Specialists Phoenix
    Code postal vérifié
    Phoenix, États-Unis· Recrutement
  • University of California Irvine
    Code postal vérifié
    Irvine, United States· Recrutement
  • University of Miami
    Code postal vérifié
    Miami, États-Unis· Recrutement
  • University of South Florida
    Code postal vérifié
    Tampa, États-Unis· Recrutement
  • Ada West Research
    Code postal vérifié
    Meridian, United States· Pas encore en recrutement
  • Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995
    Code postal vérifié
    Indianapolis, États-Unis· Recrutement
  • Hôpital Brigham and Women's
    Code postal vérifié
    Boston, États-Unis· Recrutement
  • University of Michigan
    Code postal vérifié
    Ann Arbor, États-Unis· Recrutement
  • Dartmouth Hitchcock Clinics Heater Road
    Code postal vérifié
    Lebanon, United States· Recrutement
  • Dermatology at Lake Success
    Code postal vérifié
    Lake Success, United States· Recrutement
  • Icahn School of Medicine at Mount Sinai
    Code postal vérifié
    New York, États-Unis· Recrutement

Questions fréquentes

What is pyoderma gangrenosum (PG)?

Pyoderma gangrenosum is a rare skin condition that causes painful sores or ulcers, especially on the legs. It's not an infection but is thought to be an autoimmune problem.

Qu'est-ce qu'un placebo ?

A placebo is a substance that looks exactly like the real medicine but contains no active ingredients. It helps researchers compare the effects of the actual drug against no treatment.

Why do some people get a placebo?

Giving some participants a placebo helps doctors understand if the new medicine is truly working or if improvements are due to other factors. This makes the study results more reliable.

Combien de temps vais-je participer à l'étude ?

You will be in this study for approximately 1.5 years (about 18 months).

Can I stop participating in the study at any time?

Yes, you have the right to withdraw from the study at any point, for any reason, without it affecting your medical care.

Comment en savoir plus

Boehringer Ingelheim

Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.

Intéressé à participer ?

Inscrivez votre intérêt

Partagez vos coordonnées et l'équipe de recherche pour "A Study to Test Whether Spesolimab Helps People With a Skin … vous contactera si vous êtes éligible. Consultez toujours votre médecin avant d'accepter de participer.

Discussion

Discussion communautaire

Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.